Intelligent Medicine Acquisition Corp. Announces Pricing of Upsized $180,000,000 Initial Public Offering

Rhea-AI Summary

Intelligent Medicine Acquisition Corp. (NASDAQ: IQMDU) announced the pricing of its upsized initial public offering of 18,000,000 units at $10.00 each, with trading expected to begin on November 5, 2021. Each unit consists of one share of common stock and one-half of a redeemable warrant, with each whole warrant entitling the holder to purchase one full share at $11.50. The offering is projected to close on November 9, 2021. The company aims to focus on life science businesses utilizing AI and big data for drug discovery, with Cantor Fitzgerald as the sole book running manager for the offering.

Positive

• Successful pricing of an upsized IPO of 18 million units at $10.00 each, indicating strong market interest.
• Focus on life sciences and AI-driven drug discovery, potentially positioning the company for significant growth.

Negative

• There are no guaranteed outcomes for the IPO completion or business combination, as stated in the forward-looking statements.
• Potential market risks include integration challenges post-merger and reliance on successful identification of a business combination.

BETHESDA, Md.--(BUSINESS WIRE)-- Intelligent Medicine Acquisition Corp. (NASDAQ: IQMDU) (the “Company” or “Intelligent Medicine”) today announced the pricing of its upsized initial public offering of 18,000,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Global Market (NASDAQ) and are expected to trade under the ticker symbol “IQMDU” beginning on November 5, 2021. Each unit consists of one share of common stock and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder to purchase one share of common stock of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the shares and warrants are expected to be traded on NASDAQ under the symbols “IQMD” and “IQMDW,” respectively. The offering is expected to close on November 9, 2021, subject to customary closing conditions.

Intelligent Medicine was formed for the purpose of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Although the Company’s efforts to identify a prospective business combination opportunity will not be limited to a particular industry, it intends to focus on life science companies that are using artificial intelligence, machine learning and big data to power drug discovery.

Cantor Fitzgerald & Co. is the sole book running manager for the offering. The manager has a 45-day option to purchase up to an additional 2,700,000 units solely to cover over-allotments, if any.

A registration statement relating to the securities became effective on November 4, 2021. The offering was made only by means of a prospectus, copies of which may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, c/o Cantor Fitzgerald & Co., 499 Park Avenue, 5th Floor, New York, New York 10022, or by email at prospectus@cantor.com. Copies of the registration statements can also be accessed through the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and the Company’s plans with respect to the target industry for a potential business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the Company will ultimately complete a business combination transaction. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the SEC. Copies of these documents are available on the SEC’s website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006395/en/

Brian Ruby, ICR, brian.ruby@icrinc.com

Source: Intelligent Medicine Acquisition Corp.

FAQ

What is the IPO price for IQMDU?

The IPO price for Intelligent Medicine Acquisition Corp. (NASDAQ: IQMDU) is set at $10.00 per unit.

When will IQMDU start trading on NASDAQ?

Trading for IQMDU is expected to begin on November 5, 2021.

What does each unit of IQMDU consist of?

Each unit for IQMDU consists of one share of common stock and one-half of a redeemable warrant.

What is the purpose of Intelligent Medicine Acquisition Corp.?

The company aims to merge with or acquire businesses in the life sciences sector that leverage AI and big data for drug discovery.